undamentalytics Newsletter
Sign in

Institution

Alphabet Inc.

13F for the quarter to June 30, 2026, filed August 7, 2026 · SEC CIK 1652044

Reported value
$99.1bn
100% in companies we cover
Positions we cover
28
Largest SPCX 95.0%
Copy, a year
+35.0%
S&P 500 +19.3%
Copy Sharpe ratio
0.83
S&P 500 1.00

How copying its 13F would have done

$10.0k$20.0k$40.0k 20222023202420252026 $32.8k$20.1k
CopyS&P 500 $10,000 copying Alphabet Inc.'s filed holdings in companies we cover from November 18, 2022, buying on the first trading day after each 13F was filed and holding until the next, against the S&P 500 (total return). Marked weekly, log scale. Before costs and taxes; misses trading within each quarter and anything 13F does not show (shorts, cash, bonds, non-US holdings).

Biggest drop −36.2% (S&P 500 −16.9%); beta 1.91; alpha +6.7% a year (t = 0.44); last 12 months +27.7% against +12.1%.

Reported value by quarter

Alphabet Inc.: 13F reported value Total value of all positions in each quarter's 13F, as filed (values before 2023 were filed in thousands of dollars and are converted).
$0 $500B $1T $1.5T $2T Reported value, 2018-06-30: $1.2B Reported value, 2018-09-30: $1B Reported value, 2019-03-31: $1.9B Reported value, 2019-06-30: $5.3B Reported value, 2019-09-30: $3.3B Reported value, 2019-12-31: $1.7B Reported value, 2020-03-31: $1.5B Reported value, 2020-06-30: $2.2B Reported value, 2020-09-30: $2.1B Reported value, 2020-12-31: $2.1B Reported value, 2021-03-31: $2.5B Reported value, 2021-06-30: $4.9B Reported value, 2021-09-30: $4.2B Reported value, 2021-12-31: $4.1B Reported value, 2022-03-31: $3.1B Reported value, 2022-06-30: $1.8B Reported value, 2022-09-30: $2B Reported value, 2022-12-31: $1.7T Reported value, 2023-03-31: $1.8B Reported value, 2023-06-30: $1.9B Reported value, 2023-09-30: $1.6B Reported value, 2023-12-31: $2.2B Reported value, 2024-03-31: $2.5B Reported value, 2024-06-30: $2B Reported value, 2024-09-30: $1.8B Reported value, 2024-12-31: $1.7B Reported value, 2025-03-31: $1.6B Reported value, 2025-06-30: $2.1B Reported value, 2025-09-30: $2.4B Reported value, 2025-12-31: $2.6B Reported value, 2026-03-31: $4B Reported value, 2026-06-30: $99.1B 2018-06-30 2020-06-30 2022-03-31 2023-12-31 2026-06-30 $99.1B
View chart data
Period Reported value
2018-06-30 $1.2B
2018-09-30 $1B
2019-03-31 $1.9B
2019-06-30 $5.3B
2019-09-30 $3.3B
2019-12-31 $1.7B
2020-03-31 $1.5B
2020-06-30 $2.2B
2020-09-30 $2.1B
2020-12-31 $2.1B
2021-03-31 $2.5B
2021-06-30 $4.9B
2021-09-30 $4.2B
2021-12-31 $4.1B
2022-03-31 $3.1B
2022-06-30 $1.8B
2022-09-30 $2B
2022-12-31 $1.7T
2023-03-31 $1.8B
2023-06-30 $1.9B
2023-09-30 $1.6B
2023-12-31 $2.2B
2024-03-31 $2.5B
2024-06-30 $2B
2024-09-30 $1.8B
2024-12-31 $1.7B
2025-03-31 $1.6B
2025-06-30 $2.1B
2025-09-30 $2.4B
2025-12-31 $2.6B
2026-03-31 $4B
2026-06-30 $99.1B

Holdings and moves

CompanyShare of portfolioValueSharesChange in shares
SPCXSpace Exploration Technologies Corp95.05%$94.2bn551.19MNew
PLPlanet Labs PBC1.18%$1.2bn35.25M0.0%
ASTSAST Spacemobile, Inc.0.80%$794.7m8.94M0.0%
CMECME Group0.78%$769.4m3.48M0.0%
ARMARM Holdings PLC0.70%$695.2m1.96M0.0%
RVMDRevolution Medicines, Inc.0.56%$551.8m2.95M−10.5% Reduced
FRSHFreshworks Inc.0.17%$164.0m16.21M0.0%
PBLSParabilis Medicines, Inc.0.14%$134.6m4.92MNew
TEMTempus AI, Inc.0.09%$89.9m1.55M0.0%
GTLBGitlab Inc.0.08%$83.2m2.72M0.0%
PATHUipath, Inc.0.08%$76.5m7.03M0.0%
LIFEEthos Technologies Inc.0.07%$65.7m3.62M−3.9% Reduced
PRMEPrime Medicine, Inc.0.06%$61.1m16.56M0.0%
FRVOFervo Energy Co0.05%$51.5m1.76MNew
PAYPPaypay Corp0.04%$44.8m3.13M0.0%
MAZEMaze Therapeutics, Inc.0.04%$41.4m1.39M0.0%
RLAYRelay Therapeutics, Inc.0.03%$26.4m1.41M−9.9% Reduced
BBOTBridgebio Oncology Therapeutics, Inc.0.02%$21.5m2.82M0.0%
OSCROscar Health, Inc.0.01%$13.7m482.0K0.0%
BEAMBeam Therapeutics Inc.0.01%$11.0m321.6K0.0%
VERAVera Therapeutics, Inc.0.01%$10.4m241.3K0.0%
SANASana Biotechnology, Inc.0.01%$9.8m2.81M0.0%
GLUEMonte Rosa Therapeutics, Inc.0.01%$9.0m372.5K−45.6% Reduced
LYELLyell Immunopharma, Inc.0.00%$4.1m293.3K0.0%
FIGFigma, Inc.0.00%$3.9m215.6K0.0%
SPROSpero Therapeutics, Inc.0.00%$2.0m890.0K0.0%
HYPRHyperfine, Inc.0.00%$1.2m898.7K0.0%
AUTLAutolus Therapeutics plc0.00%$1.1m698.3K0.0%
CompanyBought (value)Shares
SPCXSpace Exploration Technologies Corp$94.2bn551.19M
PBLSParabilis Medicines, Inc.$134.6m4.92M
FRVOFervo Energy Co$51.5m1.76M

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanySold (value)Shares
RVMDRevolution Medicines, Inc.−$64.8m−345.9K
GLUEMonte Rosa Therapeutics, Inc.−$7.5m−311.8K
RLAYRelay Therapeutics, Inc.−$2.9m−154.1K
LIFEEthos Technologies Inc.−$2.7m−147.6K
TNYATenaya Therapeutics, Inc.−$631,836−915.7K

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanyValue last quarterShares
TNYATenaya Therapeutics, Inc.$631,836915.7K
  • Industrials96.2%
  • Technology1.1%
  • Health Care1.0%
  • Communication Services0.8%
  • Financials0.8%
  • Utilities0.1%

Share of the value held in companies we cover, by sector.

PeriodCopy, a yearS&P 500SharpeS&P 500Biggest dropBeta
Whole backtestNovember 18, 2022 to November 2, 2026+35.0%+19.3%0.831.00−36.2%1.91
Last three yearsNovember 3, 2023 to November 2, 2026+46.8%+21.8%1.021.16−36.2%1.85
Last yearNovember 7, 2025 to November 2, 2026+40.4%+14.2%0.870.84−29.4%2.01

From SEC Form 13F data sets. A 13F lists long positions in US-listed shares at the quarter's end, filed up to 45 days later; it does not show shorts, cash, bonds, non-US holdings or trades within the quarter. Positions in companies outside our coverage are not listed here. Research, not investment advice.